Pentostam (sodium stibogluconate) is an established medication utilized in the management of leishmaniasis, a parasitic infection transmitted through the bite of certain sandflies. The medication is indicated for use in several clinical presentations of the disease.

Quick Facts

• Visceral Leishmaniasis (Kala-Azar): Supports the clinical management of this serious form of the disease that affects internal organs.
• Cutaneous Leishmaniasis: Employed in the treatment of the skin lesions and ulcers associated with this form.
• Mucocutaneous Leishmaniasis: Used to address the involvement of the mucous membranes of the nose, mouth, and throat.

The medication functions to combat the protozoal parasites responsible for the condition. It is utilized within these specific therapeutic domains and serves as a key component of supportive care protocols in endemic regions globally. The medication is available through specific access protocols for the treatment of these parasitic infections.

Pentostam (Sodium Stibogluconate) eligibility is strictly defined by specific exclusions and population restrictions documented in official regulatory prescribing information. Use of the medicine is formally prohibited in several key populations due to significant safety concerns.

Contraindicated Populations

• Individuals with a known hypersensitivity to sodium stibogluconate or any of its ingredients.
• Patients with significantly impaired renal function (severe kidney disease or renal failure).
• Women who are breastfeeding.

Conditional and Restricted Use

The label requires significant caution or prohibits use in patients with certain comorbidities. Use is restricted or contraindicated in individuals with cardiac disease, especially pre-existing arrhythmia, and those with severe liver disease/failure. Additionally, use may be contraindicated in patients with severe malnutrition or advanced HIV infection.

While the drug is used across age groups for Leishmaniasis, official documentation notes little information is available regarding the effects on older individuals, necessitating strict adherence to precautions. The medicine should be withheld during pregnancy unless the clinical benefit is determined to outweigh the risk to the fetus.

Interactions with other medicines and products

Pentostam (Sodium Stibogluconate) has officially documented interaction patterns that are primarily based on additive pharmacodynamic effects rather than metabolic interference. The regulatory profile emphasizes risks associated with enhanced toxicity, particularly to the heart.

Pharmacodynamic Interaction Risks

The co-administration of sodium stibogluconate with specific drug classes or compounds can increase the potential for adverse effects. The use of Pentostam alongside Amphotericin B deoxycholate has been associated in regulatory reports with enhanced cardiotoxicity, including reports of cardiac arrhythmias and sudden death. Close monitoring is required when used with other antimonial drugs due to the risk of cumulative antimony intoxication. Furthermore, concurrent use with QTc-prolonging agents may increase the risk of QTc interval prolongation.

Administration Restrictions

Specific restrictions concerning timing and patient condition are documented to manage these risks:

• Timing Separation: For retreatment of visceral leishmaniasis, regulatory guidance suggests allowing a minimum 14-day resting period between the cessation of sodium stibogluconate and the initiation of Amphotericin B deoxycholate.
• Physiological Constraint: Before co-administering Amphotericin B deoxycholate, electrolyte imbalances must be corrected, as these imbalances can compound the documented cardiotoxicity risk.

No specific interactions are officially documented in regulatory labels for Pentostam regarding food, alcohol, or common herbal products. The interaction profile does not include specific statements on CYP enzyme or transporter-mediated pharmacokinetic effects.

Pentostam, or sodium stibogluconate, contains pentavalent antimony (Sb(V)), which is converted intracellularly to the trivalent antimony (Sb(III)) active species. The active Sb(III) primarily targets key metabolic pathways within the Leishmania amastigote. This species acts as a non-competitive inhibitor of multiple glycolytic enzymes, including phosphofructokinase and pyruvate kinase, leading to a reduction in glucose catabolism. This inhibitory interaction compromises the parasite's energy metabolism, severely reducing the synthesis of adenosine triphosphate (ATP) and guanosine triphosphate (GTP) from their respective diphosphates. The resultant decrease in purine nucleoside triphosphates leads to a downstream cascade: the inhibition of macromolecular synthesis, specifically DNA, RNA, and protein production. Furthermore, Sb(III) is postulated to inhibit DNA topoisomerase I and interfere with the thiol-dependent redox system within the parasite by binding to vital thiol groups. These combined intracellular consequences modulate the parasite's fundamental cellular processes, leading to loss of viability.

Official Instructions for Pentostam Use

The usage of Pentostam (Sodium Stibogluconate) is strictly defined by standardized clinical protocols and is limited to parenteral administration in a supervised clinical setting. These usage principles define precise calculations for dosing and the required duration of treatment.

Administration Scope

Course Duration

The full course of treatment is time-bound and must be completed at the full daily dose.

Connection to the Overall Use Protocol

Official instructions mandate a standardized, weight-based regimen that requires the drug to be delivered daily by injection for a defined, continuous period. The requirements for slow IV infusion and medical supervision dictate the clinical setting in which Pentostam must be utilized to maintain procedural integrity.

Research Evidence / Overview of Studies for Pentostam

Evidence for Use in Visceral Leishmaniasis (Kala-Azar)

Visceral Leishmaniasis (Kala-Azar) is a systemic condition characterized by functional imbalance, and research for Pentostam was primarily conducted in this area. Research has primarily examined its use in studies involving the parasitic infection that affects internal organs. The evidence base includes many randomized controlled trials (RCTs)—a key type of study for medical evaluation—and large observational studies conducted in the regions where the disease is most common.

Researchers studied what outcomes were measured when treated with Pentostam alone versus when it was used as part of a combination treatment alongside another anti-leishmanial drug. Studies monitored outcomes related to systemic or functional imbalance, such as parasite presence in tissue samples (like the spleen), and changes in clinical signs like fever and spleen size. Findings often indicate patterns related to the final outcome status, though these findings were mixed and varied depending on the geographical location where the study was conducted.

Studies Comparing Single-Drug Therapy vs. Combination Regimens

This subsection summarizes trials that investigated the use of Pentostam alone versus its use alongside other anti-leishmanial agents. These comparative studies were designed to evaluate different treatment approaches. They monitored whether the combination approach was associated with different measured outcomes compared to using Pentostam as a single agent.

Evidence for Use in Cutaneous Leishmaniasis

For Cutaneous Leishmaniasis, research has explored how Pentostam was studied for the skin lesions and ulcers associated with this condition. The research includes randomized controlled trials (RCTs) that compared using Pentostam systemically versus applying it directly to the lesion. The studies monitored outcomes linked to inflammatory or irritative states, such as the measured status of re-epithelialization of the lesions and changes in their size or number. Research highlights changes measured during the study period, which were often found to be highly dependent on the specific species of the Leishmania parasite causing the infection.

Gaps and Uncertainty in the Research Evidence

Despite its historical context of study, research has explored areas where data show patterns related to uncertainty. Certainty remains low regarding the use of single-drug therapy in regions where parasite resistance has been observed. Furthermore, comparative evidence is lacking in some areas, as much of the recent high-quality research focuses on combination regimens. The available evidence provides insight into short-term changes, but long-term outcomes are not fully established across all patient groups.

Common questions about Pentostam (FAQ)

Q: What should I do if I miss a dose?

If a scheduled dose is missed, it is important to contact your doctor or healthcare professional immediately. Official dosing protocols emphasize the importance of continuous treatment, and you will require specific instructions from your care team on how to proceed.

Q: Will I experience pain at the injection site?

Pain, redness, or irritation at the injection site is a reported adverse effect, according to official product information and clinical reports. This local reaction is noted to be particularly common when the medicine is administered via intralesional or intramuscular injection.

Q: Does Sodium Stibogluconate interact with common pain relievers (like ibuprofen or paracetamol)?

Official drug interaction information generally lists medicines that are known to prolong the QT interval as potential risks. However, common, over-the-counter pain relievers are not typically listed as specific contraindications. Official guidance advises discussing all current medicines and supplements with the medical team.

Q: Can this medicine affect the results of my medical tests?

Official information indicates that the use of this medication can cause temporary changes in lab test results. These changes include elevated liver enzymes, elevated pancreatic enzymes (amylase and lipase), and certain abnormalities in blood cell counts. ECG changes, such as a prolonged QT interval, are also noted in safety information.

Q: Is this medication available under other brand names globally?

The active ingredient, sodium stibogluconate, is the official non-proprietary name for the medicine. The drug is widely recognized and historically marketed under the brand name Pentostam in various regions across the world.

Q: Can I expect to feel tired or weak while on this treatment?

Regulatory documents and official side effect reports indicate that a general feeling of being unusually tired or weak, known as lethargy, is a reported adverse effect. Any severe or persistent symptom should be discussed with the treating physician.

Q: Will the medicine cause me to lose my appetite?

Loss of appetite, or anorexia, is a commonly reported adverse effect noted in the official safety profile for sodium stibogluconate. This is often associated with other gastrointestinal effects like nausea or vomiting.

Q: Will I get a metallic taste in my mouth?

A metallic taste in the mouth is described in clinical features and official side effect reports. This adverse effect is reported to be associated with the way the medicine is administered parenterally (by injection).

Q: How long does the medicine stay in my system?

Pharmacokinetic studies indicate that Sodium Stibogluconate has a reported elimination half-life of approximately six hours. The compound is then rapidly cleared from the body primarily through the kidneys.

Q: Can Sodium Stibogluconate affect my blood cell counts?

Official safety data indicates that use of this medication can lead to hematological abnormalities. These changes may include transient thrombocytopenia (a low platelet count) and leukopenia (a low white blood cell count).

Q: Are weight loss or weight gain common side effects?

Weight loss is not explicitly listed in official adverse reaction tables. However, loss of appetite (anorexia) is a common side effect, which may be indirectly related to changes in body weight due to reduced food intake or reported gastrointestinal effects.

Q: Can I drive or operate heavy machinery while receiving this medicine?

Official information reports side effects such as tiredness, dizziness, and vertigo (a spinning sensation). These effects could potentially impair your ability to drive or safely operate machinery, and patients should exercise caution.

Official Storage and Disposal Requirements for Pentostam (Sodium Stibogluconate)

Pentostam must be stored strictly according to regulatory labeling to maintain its efficacy and ensure safety.

Storage Conditions:

• Temperature: Store below 25 C.
• Protection: Do not freeze. Keep the vial in the original carton to protect it from light.
• Children: Keep this medicine out of the sight and reach of children.

Stability and Handling:

• For the multi-dose container, the contents must not be used more than 1 month after the first dose is withdrawn.
• The product must be filtered immediately before use due to potential particulates.

Disposal Rules:

• Dispose of all unused medicine and sharps (needles) according to local pharmaceutical waste procedures.
• Due to the environmental classification of sodium stibogluconate, disposal must be managed to avoid release into the environment, such as through household trash or wastewater.